公开(公告)号：US20240342322A1

公开(公告)日：2024-10-17

申请号：US18291972

申请日：2022-07-26

Applicant: NETRIS PHARMA ,  Centre national de la recherche scientifique ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (INSERM) ,  Université Claude Bernard Lyon 1 ,  CENTRE LEON BERARD ,  HOSPICES CIVILS DE LYON

Inventor： Mathieu RICHAUD ,  Jennifer WISCHHUSEN ,  David NEVES ,  Patrick MEHLEN ,  David SARRUT ,  Benjamin GIBERT ,  David KRYZA

IPC: A61K51/10 ,  A61P35/00 ,  C07K16/22

CPC classification number: A61K51/1021 ,  A61K51/1096 ,  A61P35/00 ,  C07K16/22 ,  A61K2121/00 ,  A61K2123/00 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/92

Abstract: The present invention is based on the finding that Netrin-(1) is retained in a stickier manner in the cell matrix at the cell periphery of the cancer cells, whereas Netrin-(1) is expressed in adults specifically in some tumors. It is also shown herein that Netrin-(1) is expressed very early during tumor formation. This makes Netrin-(1) an unexpected very specific target for imagery and/or targeted therapy. The present invention thus relates to compounds comprising an anti-Netrin-1 antibody, especially NP(137), a chelating moiety, optionally associated with a radioisotope, and their use either in imagery, diagnosis, especially companion diagnosis, or in targeted therapy. New diagnostic tests, which may be companion tests, and new cancer therapies, that may be combined to the companion test, are also proposed.

公开(公告)号：US12110556B2

公开(公告)日：2024-10-08

申请号：US17729115

申请日：2022-04-26

Applicant: BIOMERIEUX ,  HOSPICES CIVILS DE LYON ,  UNIVERSITE CLAUDE BERNARD LYON 1

Inventor： Elisabeth Cerrato ,  Benjamin Delwarde ,  Guillaume Monneret ,  Estelle Peronnet ,  Julien Textoris ,  Fabienne Venet

IPC: C12Q1/6883 ,  C12Q1/6806 ,  C12Q1/686

CPC classification number: C12Q1/6883 ,  C12Q1/6806 ,  C12Q1/686 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: A kit for in vitro measurement of a at least one IL7R gene transcript in a blood sample, including specific reagents for measuring the transcript, and a control sample calibrated to contain the IL7R gene transcript corresponding to the mean quantity measured in a pool of reference blood samples from human patients in a state of septic shock when reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and who were known to have survived, and/or a calibrated to contain the quantity of an IL7R gene transcript corresponding to the mean quantity measured in reference blood samples from patients in a state of septic shock when the reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and not to have survived.

公开(公告)号：US20240193779A1

公开(公告)日：2024-06-13

申请号：US18555618

申请日：2022-04-27

Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  UNIVERSITE GRENOBLE ALPES ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  HOSPICES CIVILS DE LYON ,  CENTRE LEON BERARD ,  UNIVERSITÉ CLAUDE BERNARD LYON 1

Inventor： Rémi SOUCHON ,  Tristan JAOUEN ,  Au HOANG-DINH ,  Christelle GONINDARD ,  Olivier ROUVIERE

IPC: G06T7/00

CPC classification number: G06T7/0016 ,  G06T2207/10088 ,  G06T2207/30081

Abstract: The invention relates to a system and a method for computer-aided detection (CAD) of aggressive prostate cancers. The automatic diagnosis of aggressive prostate cancers is difficult and methods that work with some MRI scanners do not work as well when implemented on images from different scanners. By studying a data base containing MRI data and biopsy results from 265 patients, acquired by 4 different types of MRI scanners, using machine learning techniques, the inventors established a method for automatically determining the presence of aggressive cancers, this methods showing high sensitivity and specificity when implemented on another database containing MRI data from 270 patients, acquired by different MRI scanners than the first database. The method involves feeding MRI images to a system calculating a score for a portion of the prostate and determines that the portion contains an aggressive cancer based on whether a criterion depending on the score is verified.

公开(公告)号：US20220381791A1

公开(公告)日：2022-12-01

申请号：US17766155

申请日：2020-09-30

Applicant: BIOMÉRIEUX ,  HOSPICES CIVILS DE LYON ,  UNIVERSITE CLAUDE BERNARD LYON 1

Inventor： Sophie ASSANT ,  François MALLET ,  François BARTOLO ,  Chloé ALBERT VEGA

IPC: G01N33/68 ,  C07K16/28 ,  C12Q1/6813 ,  C12Q1/6844

Abstract: An in vitro or ex vivo method for determining the ability of an individual to respond to a stimulus, based on the measurement of the expression of at least two different biomarkers, selected from different lists among three lists of biomarkers, from a blood sample of the individual, incubated with the stimulus, as well as tools allowing the implementation of this method and the use of these tools.

公开(公告)号：US20220296606A1

公开(公告)日：2022-09-22

申请号：US17828245

申请日：2022-05-31

Applicant: UNIVERSITE CLAUDE BERNARD LYON 1 ,  INSTITUT NATIONAL DE SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  HOSPICES CIVILS DE LYON ,  UNIVERSITE LAVAL

Inventor： Manuel ROSA-CALATRAVA ,  Olivier TERRIER ,  Julien TEXTORIS ,  Guy BOIVIN ,  Mario PIZZORNO

IPC: A61K31/55 ,  A61P31/16 ,  A61K45/06 ,  A61K9/00 ,  A61K31/215 ,  A61K31/665 ,  A61K31/196 ,  A61K31/13 ,  A61K31/4025

Abstract: The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. The composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

公开(公告)号：US11339438B2

公开(公告)日：2022-05-24

申请号：US15780573

申请日：2016-12-01

Applicant: BIOMERIEUX ,  HOSPICES CIVILS DE LYON ,  UNIVERSITE CLAUDE BERNARD LYON 1

Inventor： Elisabeth Cerrato ,  Benjamin Delwarde ,  Guillaume Monneret ,  Estelle Peronnet ,  Julien Textoris ,  Fabienne Venet

IPC: C12Q1/6883 ,  C12Q1/6806 ,  C12Q1/686

Abstract: The invention concerns a method of in vitro or ex vivo evaluation of the risk of complications in a patient who has sustained an insult or an infection generating a systemic inflammatory response syndrome, the method being characterized in that it comprises the step of detecting, in a biological sample obtained from said patient, at least one transcript of the IL7R gene, as well as measuring, in vitro or ex vivo, the quantity of at least one transcript of the IL7R gene, in a biological sample from a patient who has sustained an insult or an infection generating a systemic inflammatory response syndrome, in order to evaluate the risk of complications, and in particular of mortality, in said patient.
The invention also concerns kits for measuring, in vitro or ex vivo, the quantity of at least one transcript of the IL7R gene in a biological sample.

公开(公告)号：US20210364660A1

公开(公告)日：2021-11-25

申请号：US16982429

申请日：2019-03-20

Applicant: UNIVERSITE CLAUDE BERNARD LYON 1 ,  INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  HOSPICES CIVILS DE LYON ,  CPE LYON FORMATION CONTINUE ET RECHERCHE ,  ECOLE CENTRALE DE LYON

Inventor： Patrick PITTET ,  Guo-Neng LU ,  Patrice JALADE ,  Jean-Marc GALVAN

IPC: G01T1/20

Abstract: A multilayer scintillation detector, includes at least three layers superposed on one another, and each extending parallel to a plane, called the detection plane, wherein each layer is formed by a first material, called a scintillation material, capable of interacting with an ionizing radiation and of forming, following the interaction, a scintillation light in a scintillation spectral band; each layer has a plurality of light guides, respectively extending parallel to the detection plane, according to a length, the light guides being disposed, over all or part of their length, parallel to an axis of orientation; the axis of orientation of the light guides of each layer is oriented, in the detection plane, according to an orientation, the orientations of the respective axes of orientation of at least three layers being different from one another, such that each layer has an associated orientation; and the scintillation material has a first refractive index.

公开(公告)号：US20190292546A1

公开(公告)日：2019-09-26

申请号：US16348775

申请日：2017-11-10

Applicant: Centre Léon-Bérard ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  Centre national de la recherche scientifique ,  Université Claude Bernard Lyon 1 ,  HOSPICES CIVILS DE LYON

Inventor： Serge LEBECQUE ,  Toufic RENNO ,  Béatrice VANBERVLIET ,  Yann ESTORNES

IPC: C12N15/117 ,  C12N5/09 ,  A61K31/337 ,  A61N5/10

Abstract: The present invention relates to a TLR3 agonist for use for inducing apoptosis in senescent cancer cells, in particular to a TLR3 agonist for use as a medicament for inducing apoptosis in senescent cancer cells. In particular, it relates to a TLR3 agonist for use for the treatment of cancer, optionally in combination with a chemotherapeutic agent or with radiotherapy. It further relates to a pharmaceutical composition comprising a TLR3 agonist and a chemotherapeutic agent.

公开(公告)号：US20190076484A1

公开(公告)日：2019-03-14

申请号：US15762775

申请日：2016-09-23

Applicant: Universite Claude Bernard Lyon 1 ,  Hospices Civils de Lyon ,  University of Washington

Inventor： Laurence Josset ,  Maxime Pichon ,  Bruno Lina ,  Michael Katze ,  Stanley Langevin

IPC: A61K35/74 ,  G01N33/569

Abstract: The present invention relates to the use of at least one biomarker for predicting the severity of a disease caused by the infection of an individual with an influenza virus, wherein said biomarker is selected in a group comprising (i) the alpha diversity value of the microbiome present in a respiratory sample of said individual and (ii) the microbiome profile of the said respiratory sample.

公开(公告)号：US20170362578A1

公开(公告)日：2017-12-21

申请号：US15507620

申请日：2015-08-28

Applicant: CALIXAR ,  Université Claude Bernard Lyon 1 ,  Hospices Civils de Lyon ,  INSERM

Inventor： Manuel ROSA-CALATRAVA ,  Aurélien TRAVERSIER ,  Élodie DESUZINGES-MANDON ,  Emmanuel DEJEAN

IPC: C12N7/04 ,  A61K39/145 ,  C07C39/17 ,  A61K39/00

CPC classification number: C12N7/04 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/5252 ,  C07C39/17 ,  C12N7/00 ,  C12N2760/16134 ,  C12N2760/16151

Abstract: The present invention relates to a method for preparing a vaccine antigen, which includes a step of fragmenting a biological membrane associated with said vaccine antigen by treating said biological membrane with at least one calixarene of formula (II): wherein: X is a —(CH2)-CO2Y group and Y is an alkaline metal or one of the pharmaceutically acceptable salts thereof, wherein said resulting vaccine antigen also includes a fragment of the biological membrane associated with said antigen. The present invention also relates to a vaccine that can be produced by implementing the method, including a calixarene of formula (II) in carrier format, with a quantity of 0.1 to 1,000 μg in the total weight of the vaccine. The present invention further relates to the use of a calixarene as defined above for the preparation of a vaccine or a vaccine antigen, and to the vaccine for use as a drug in the treatment or prevention of an infectious disease.